Vascular Access for Therapeutic Plasma Exchange

Abstract: Adequate venous access is an essential component of therapeutic plasma exchange (TPEX). The simplest kind of venous access is venipuncture of antecubital veins, but this technique may be limited by venous size or scarring following the procedure, requiring the placement of a specialized vascular access device (VAD). VADs provide reliable central venous access and may remain in place for several weeks or months, depending on the VAD and the venous site chosen. Their use, however, is potentially limited by the risk of complications. We discuss indications for insertion, choice of catheter and access site, and complications of VAD placement for TPEX.     

检测胞浆抗原用于急性白血病免疫分型

目的:探讨胞浆抗原在急性白血病免疫分型中的临床意义。方法:用流式细胞仪检测42例初治急性白血病患者胞浆抗原CyCD_3,CyCD_(22),CyCD_(79a)和MPO。结果:T—ALL阳性胞浆抗原主要表达在CyCD_3,阳性率占88.9％。B—ALL阳性胞浆抗原主要表达在CyCD_(79a),AML主要表达CyMPO。结论:CyCD_3和CyCD_(79a),及MPO可分别作为T—ALL,B—ALL和AML系列特异性标志,对正确诊断白血病提供非常有价值的依据。     

ADM对LNNA诱导的高血压心肌肥大的作用及机制探讨

本工作在ＬＮＮＡ经慢性ＮＯ封闭诱导的大鼠高血压心肌肥大模型上研究了ＡＤＭ对其心肌肥大和Ｍ５ＬＶ钠一钙交换功能损伤的作用。结果：一、较之对照组，ＬＮＮＡ组ＭＡＯ和ＬＶＩ分别增加５７．４％和１８。０％（Ｐ＜０．０１）．其ＭＳＬＶ经钠－钙交换蛋白的钙摄取则明显降低（Ｐ＜０．０１或０．０５）：二．ＡＤＭ组的ＭＡＰ和ＬＶＩ则分别较ＬＮＮＡ组降低１９．６％和１１．３％，而其ＭＳＬＶ的钙摄取则高于ＬＮＮＡ组（Ｐ＜０．０５）；三、对照组、ＬＮＮＡ组和ＡＤＭ组钠－钙交换蛋白摄取钙的Ｋｍ值分别为７．５１．７．０４和７．５７ｕＭ，而Ｖｍａｘ则分别为６．３８，４．３２和５．４５ｎｍｏｌ／。ｍｇｐｒ／ｍｉｎ。表明：ＡＤＭ能拮抗ＬＮＮＡ诱导的高血压心肌肥大和减轻其ＭＳｌｌＶ钠－钙交换功能的损伤，并且后者可能是ＡＤＭ拮抗心肌肥大的机制之一。揭示内源性ＡＤＭ的诱导和外源性给予ＡＤＭ可能有预防和／或延缓高血压心肌肥大发生发展的作用。     

Subacute (acute,persistent) thrombotic microangiopathy

Six patients with prolonged acute courses of thrombotic microangiopathy are reviewed. These patients had in common courses of acute disease requiring plasma support for more than 3 months, with subsequent complete remission. Plasma support requirements may be prodigious, and the acute course may require more than 100 plasma exchanges before a stable remission is achieved. These patients appear to represent a subset of thrombotic microangiopathy distinct from the more common acute T.T.P. course, which resolves in 3–6 weeks, and the chronic relapsing pattern, which may have a short or prolonged acute course. © 1992 Wiley-Liss, Inc.     

Clastogenic effect of fenfluramine in mice bone marrow cells in vivo

Fenfluramine, an amphetamine derivative used in the treatment of obesity, has been evaluated in vivo in the bone marrow cells of Swiss albino mice using two cytogenetic endpoints for assessing its genotoxic and clastogenic potentials. Concentrations of 0.75, 1.5, 3.0, and 5.0 mg/kg b.w. were administered orally for the study of sister chromatid exchange frequencies and chromosome aberrations (CA). SCE frequencies showed a positive dose response; 1.5 mg/kg being the minimum effective concentration. Fen caused a prolongation of cell cycle at all concentrations. Except for the minimum therapeutic dose (0.75 mg), all other doses (1.5, 3.0, and 5.0 mg) showed a significant increase in the percentage of damaged cells over that of the vehicle control. The degree of clastogenicity was directly proportional to the dosage used and inversely related with the duration of treatment. A gradual reduction of the clastogenic potential was observed after 12 and 24 hr of exposure, indicating that the maximum effect occurs at the middle or late synthetic phase of the cell cycle. This study, probably the first detailed screening of the drug for its genotoxicity, shows that Fen is moderately clastogenic and a DNA damaging agent in vivo.     

血浆纤维蛋白原水平在颅脑损伤病人中的变化及其意义

目的探讨血浆纤维蛋白原水平与急性单纯闭合颅脑损伤患者严重程度的相关意义。方法检测180例于伤后24h内到院的急性闭合颅脑损伤患者的格拉斯哥昏迷评分、纤维蛋白原含量。结果颅脑损伤病人血浆中纤维蛋白原水平明显降低;颅脑损伤越严重,血浆中纤维蛋白原含量越低,颅脑损伤越轻,纤维蛋白原含量越高,预后越好。结论血浆中纤维蛋白原水平与颅脑损伤严重程度存在明显相关性,可作为颅脑损伤严重程度的判断参考指标。     

肾脏疾病患者治疗前后血浆内皮素水平动态变化及其意义

目的 为了探讨肾脏疾病患者血浆内皮素水平与肾脏疾病病情程度的关系,为肾脏疾病治疗效果的评价提供依据.方法 采用放射免疫分析(RIA)观察了77例肾脏疾病患者治疗前后血浆内皮素水平的动态变化,并与60例正常对照组比较.结果 正常对照组血浆内皮素浓度为43.1±15.2ng/L,肾脏疾病患者治疗前血浆内皮素水平为161±83.8ng/L,治疗后为97.4±52.7ng/L,均高于正常对照组(P值均<0.001).肾脏疾病治疗后内皮素水平明显下降(P<0.001),与BUN,Cr水平的下降具有一定的相关性(相关系过分别为0.54,0.55).结论血浆内皮素水平随着肾脏疾病严重程度的增加而升高,血浆内皮素水平可作为肾脏疾病治疗效果评定的指标之一     

Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment

Objective: Interindividual variability in plasma concentrations of nicotine and its proximate metabolite, cotinine, is considerable during smoking and transdermal nicotine treatment, even among individuals taking in nominally similar doses of nicotine. This report explores the determinants of this variability and the utility of baseline (smoking) plasma concentrations to predict concentrations during transdermal nicotine treatment. Methods: Data were analysed from a smoking cessation study (n = 466), and from a pharmacokinetic study (n = 12). Multiple regression models examined the relationships of plasma concentrations to individual characteristics such as smoking pattern, absorbed dose of nicotine, and pharmacokinetic parameters. Results: Plasma concentrations of nicotine and cotinine were highly variable in both studies. Indirect estimates of plasma clearance (baseline plasma concentration divided by cigarettes per day) together with other factors could account for 18 to 33% of the variability during transdermal nicotine treatment in the smoking cessation study. In contrast, 75 to 99% was accounted for by direct measurements of plasma clearances and systemic dose of nicotine in the pharmacokinetic study. Conclusion: Plasma concentrations of nicotine and cotinine during transdermal nicotine treatment are poorly predicted by clinical history or baseline plasma concentrations. This is a result of inadequate characterisation of highly variable individual pharmacokinetic parameters and absorbed dose of nicotine. Considering the interindividual variability of plasma nicotine and cotinine concentrations together with the lack of clinical end-points for transdermal nicotine dosing, it seems logical to investigate the utility of a therapeutic drug monitoring approach for transdermal nicotine treatment – particularly for high dose regimens (> 22 mg per 24 hours). Received: 7 May 1996 / Accepted in revised form: 21 August 1996     

丝烈霉素C诱发小白鼠骨髓细胞姐妹染色单体互换和染色体畸变

丝裂霉素C(MMc)诱导的姐妹染色单体互换(SCE)可反映出细胞DMA损伤修复的基本过程。有关MMC诱发活体的SCE研究不多。本实验目的,就是探讨MMC诱发小白鼠骨髓细胞SCE的剂量—效应关系,并对SCE指标与染色体畸变指标,在检测机体DNA损伤上的差异作一比较研究。结果证明,MMC诱发染色体畸变能办远低于诱发SCE的能力,MMC可诱发小白鼠骨髓细胞SCE产生,SCE值随MMC剂量的增加而增加。SCE即使在低剂量诱变剂的作用下也是敏感的。     

胃癌病人NK细胞活性变化机理的初步研究

应用~(51)Cr释放试验和效靶结合试验,同时测定了正常人和胃癌病人外周血NK细胞活性与靶结合细胞数(TBC),研究了正常人及病人血浆对NK细胞功能的影响。发现正常人NK细胞活性与靶结合细胞数之间的关系呈直线正相关,但在NK活性降低的病人中靶结合细胞数却无明显改变,二者无相关性,而病人的血浆对正常人外周血NK活性则有明显的抑制作用(P<0.05),且抑制率与胃癌人NK细胞活性存有着负相关的关系,提示胃癌病人血浆具有抑制NK细胞活性的物质。